AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Adial Pharmaceuticals, Inc.

$4.9 -$1.10 (-18.33%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$6
Day Range
$4.9$6.06
Year Range
$1.31$10.75
Market Cap
4.7M
AVG Volume
340.32K
Trailing/Forward PE
-0.3/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-18
Primary Exchange
NASDAQUS
Net Income (USD) · TTM
-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-57.8M
26 Q1-7.77M
25 Q4-7.98M
25 Q3-8.05M
25 Q2-8.45M
25 Q1-8.95M
24 Q4-13.2M
24 Q3-13.05M
24 Q2-12.24M
24 Q1-8.69M
Operating Income (USD) · TTM
-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-57.68M
26 Q1-7.53M
25 Q4-7.8M
25 Q3-7.85M
25 Q2-8.3M
25 Q1-8.71M
24 Q4-8.28M
24 Q3-8.13M
24 Q2-7.27M
24 Q1-6.46M
EBITDA (USD) · TTM
-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-57.8M
26 Q1-7.77M
25 Q4-7.98M
25 Q3-8.05M
25 Q2-8.45M
25 Q1-8.95M
24 Q4-13.2M
24 Q3-13.03M
24 Q2-12.19M
24 Q1-11.24M
Cash Flows (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-11.13M
26 Q1-6.52M
25 Q4-6.49M
25 Q3-6.62M
25 Q2-6.48M
25 Q1-6.88M
24 Q4-6.92M
24 Q3-5.47M
24 Q2-5.17M
24 Q1-3.02M
EPS (USD) · TTM
-150-100-50024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-16.53
26 Q1-9.78
25 Q4-16.8
25 Q3-17.75
25 Q2-25.25
25 Q1-35.5
24 Q4-81.75
24 Q3-107.75
24 Q2-127.75
24 Q1-89
Expenses (USD) · TTM
-5M05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q211.49M
26 Q17.53M
25 Q47.8M
25 Q37.85M
25 Q28.3M
25 Q18.71M
24 Q48.28M
24 Q36.9M
24 Q26.05M
24 Q13.35M
Shares Outstanding · TTM
-1M-750K-500K-250K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADIL Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-600.37K
26 Q1-587.37K
25 Q4-676.2K
25 Q3-688.37K
25 Q2-729.29K
25 Q1-807.57K
24 Q4-796.83K
24 Q3-616.63K
24 Q2-696.74K
24 Q1-494.36K
Employee Count
010203020182019202020212022202320242025
ADIL Employee Count by quarter
PeriodEmployee Count
20256
20247
20237
202220
202121
20209
20194
20186
Free Cash Flow Yield
-400%-300%-200%-100%0%med -121.98%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ADIL Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-49.16%
Sep 26-33.83%
Aug 26-43.01%
Aug 26-38.73%
Aug 26-60.52%
Aug 26-119.56%
Jul 26-142.47%
Jul 26-171.17%
Jul 26-169.95%
Jul 26-171.17%
Jul 26-164.08%
Jun 26-185.88%
Jun 26-183.02%
Jun 26-159.68%
Jun 26-215.32%
May 26-198.27%
May 26-228.77%
May 26-344.82%
May 26-332.76%
May 26-377.02%
Apr 26-369.87%
Apr 26-358.52%
Apr 26-372.22%
Apr 26-345.79%
Mar 26-356.33%
Mar 26-292.19%
Mar 26-298.16%
Mar 26-319.34%
Feb 26-295.13%
Feb 26-304.76%
Feb 26-261.99%
Feb 26-239.32%
Jan 26-142.22%
Jan 26-129.86%
Jan 26-129.86%
Jan 26-124.44%
Jan 26-124.44%
Dec 25-129.86%
Dec 25-124.44%
Dec 25-99.56%
Dec 25-96.34%
Nov 25-96.34%
Nov 25-99.56%
Nov 25-90.51%
Nov 25-184.93%
Oct 25-174.36%
Oct 25-169.52%
Oct 25-169.52%
Oct 25-160.59%
Oct 25-152.56%
Sep 25-179.49%
Sep 25-174.36%
Sep 25-174.36%
Sep 25-174.36%
Aug 25-160.59%
Aug 25-160.59%
Aug 25-156.48%
Aug 25-97.42%
Aug 25-80.48%
Jul 25-72.59%
Jul 25-82.27%
Jul 25-94.92%
Jul 25-112.18%
Jun 25-108.88%
Jun 25-148.08%
Jun 25-105.77%
Jun 25-64.95%
May 25-53.65%
May 25-53.65%
May 25-56.09%
May 25-62.07%
May 25-55.58%
Apr 25-53.97%
Apr 25-53.97%
Apr 25-52.45%
Apr 25-59.11%
Mar 25-55.58%
Mar 25-50.32%
Mar 25-53.97%
Mar 25-49.65%
Feb 25-118.62%
Feb 25-118.62%
Feb 25-126.63%
Feb 25-121.7%
Jan 25-112.9%
Jan 25-95.62%
Jan 25-97.61%
Jan 25-91.87%
Jan 25-85.97%
Dec 24-91.87%
Dec 24-87.58%
Dec 24-85.97%
Dec 24-78.09%
Nov 24-93.71%
Nov 24-92.78%
Nov 24-88.4%
Nov 24-118.74%
Nov 24-122.27%
Oct 24-112.27%
Oct 24-122.27%
Price to Book
0100200300med 1.03Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ADIL Price to Book by quarter
PeriodPrice to Book
Sep 26145.17
Sep 26210.94
Aug 26165.91
Aug 26184.28
Aug 26117.91
Aug 261.47
Jul 261.23
Jul 261.02
Jul 261.03
Jul 261.02
Jul 261.07
Jun 260.94
Jun 260.96
Jun 261.1
Jun 260.81
May 260.88
May 260.77
May 260.51
May 260.53
May 260.33
Apr 260.33
Apr 260.34
Apr 260.33
Apr 260.36
Mar 260.35
Mar 260.42
Mar 260.41
Mar 260.39
Feb 260.5
Feb 260.48
Feb 260.56
Feb 260.61
Jan 261.03
Jan 261.13
Jan 261.13
Jan 261.18
Jan 261.18
Dec 251.13
Dec 251.18
Dec 251.48
Dec 251.53
Nov 251.53
Nov 251.48
Nov 251.62
Nov 250.63
Oct 250.67
Oct 250.68
Oct 250.68
Oct 250.72
Oct 250.76
Sep 250.65
Sep 250.67
Sep 250.67
Sep 250.67
Aug 250.72
Aug 250.72
Aug 250.74
Aug 253.32
Aug 254.02
Jul 254.46
Jul 253.93
Jul 253.41
Jul 252.88
Jun 252.97
Jun 252.19
Jun 253.06
Jun 254.98
May 256.03
May 256.03
May 255.77
May 252.74
May 253.06
Apr 253.15
Apr 253.15
Apr 253.24
Apr 252.88
Mar 253.06
Mar 253.38
Mar 253.15
Mar 253.43
Feb 250.78
Feb 250.78
Feb 250.73
Feb 250.76
Jan 250.82
Jan 250.97
Jan 250.95
Jan 251.01
Jan 251.08
Dec 241.01
Dec 241.06
Dec 241.08
Dec 241.19
Nov 240.99
Nov 241
Nov 241.05
Nov 241.02
Nov 240.99
Oct 241.08
Oct 240.99
Adial Pharmaceuticals, Inc.
ADIL
Stockpicker

Video analysis: ADIL

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ADIL

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 25 Aug 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company.

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

globenewswire.com · 17 Aug 2026

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

globenewswire.com · 16 Jun 2026

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. (“Azora”), which was previously announced by the Company on June 11, 2026.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.